AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain’s Circassia.
Duaklir, a combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, was approved in Europe in November 2014.
AstraZeneca said it expected to submit the drug to U.S. regulators in the first half of 2018 based on the data from the new trial.
Related posts:
AstraZeneca rebuilds cancer drug hopes with new lung data
ZLP unveils updated manifesto, says agenda will redirect Nigeria on positive path
Larry King reveals he was diagnosed with Lung Cancer
Smokers with HIV face higher risk from lung cancer than from AIDS
Nigeria on the path to growth – Minister
Tropical storm Pamela on path to hit Mexico
We must continue on the Path of Democracy in Africa – VP Osinbajo
NNPP On A Clear Path To Victory, No Need For Coalition-Ladipo Johnson
